View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

About ZOMETA
Renal Cell Carcinoma
Dose ZOMETA every 3 to 4 weeks

Page

1 2 3

ZOMETA^® effectively inhibits the vicious cycle of bone destruction when given 4 mg every 3 to 4 weeks⁹

Bone resorption marker decreases rapidly following administration of ZOMETA on day 1¹⁰
The effect of ZOMETA on bone resorption marker lessens after 3 to 4 weeks, indicating the need for continued dosing¹⁰

Change from baseline in bone resorption marker^*
(after single 4-mg dose of ZOMETA; N=12)¹⁰

*Urinary N-telopeptide/creatinine ratio was chosen as the surrogate marker.

Only dosing every 3 to 4 weeks has been proven effective in reducing
or delaying SREs^2,11-13

Page

1 2 3

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

ZOMETA® effectively inhibits the vicious cycle of bone destruction when given 4 mg every 3 to 4 weeks9

Only dosing every 3 to 4 weeks has been proven effective in reducing or delaying SREs2,11-13

ZOMETA^® effectively inhibits the vicious cycle of bone destruction when given 4 mg every 3 to 4 weeks⁹

Only dosing every 3 to 4 weeks has been proven effective in reducing
or delaying SREs^2,11-13